leadf
logo-loader
viewHumanigen, Inc.

Humanigen says review of lenzilumab Phase 3 study of COVID-19 by data safety monitoring board gets green light to continue

After completing their analysis, the DSMB recommended that the trial continue according to the existing trial protocol without modification

Humanigen, Inc. - Humanigen Inc says its Phase 3 registration trial of lenzilumab in patients with COVID-19 was unanimously recommended for continuation without modification by an independent DSMB after a planned interim analysis
Humanigen expects to complete the targeted enrollment of 300 patients this month with topline data available in the fourth quarter

Humanigen Inc (OTCQB:HGEN) announced Monday its Phase 3 registration trial of lenzilumab in patients with COVID-19 was unanimously recommended for continuation without modification by an independent DSMB (data safety monitoring board) after a planned interim analysis.

The DSMB, composed of independent subject matter experts, conducted a prespecified interim analysis after 50% of the expected recoveries were captured in the trial database, the company said in a statement.

The DSMB assessed the Phase 3 trial data for safety, futility, sample size and power assumptions. After completing their analysis, the DSMB unanimously recommended that the trial continue according to the existing trial protocol without modification.

READ: Humanigen says lenzilumab demonstrated 80% reduction in relative risk of invasive mechanical ventilation and/or death in coronavirus patients

"This unanimous recommendation by the independent DSMB is encouraging and marks another major milestone for Humanigen as we progress towards a potential EUA for lenzilumab in COVID-19," said CEO Dr Cameron Durrant. 

"We consider the decision to continue according to the existing protocol as a signal that the trial is progressing to plan."

Humanigen said it expects to complete the targeted enrollment of 300 patients this month with topline data available in the fourth quarter.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen chosen by National Institute of Health's upcoming coronavirus...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial. Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’...

on 07/31/2020

2 min read